Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Chemoembolization in Conjunction with Bevacizumab: Preliminary Results

19/12/2018 -  

Giammaria Fiorentini, MD, Donatella Sarti, PhD, Camillo Aliberti, MD, Riccardo Carandina, MD, Luca Mulazzani, MD, Alessandro Felicioli, MD, Stefano Guadagni, MD

Abstract

 

Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.

 

Source: https://www.jvir.org/article/S1051-0443(18)31125-4/abstract